Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 22 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Torrent Pharmaceuticals Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 21, 2024, 8:56 pm

Market Cap 1,16,318 Cr.
Current Price 3,437
High / Low 3,591/2,223
Stock P/E66.8
Book Value 222
Dividend Yield0.81 %
ROCE23.2 %
ROE24.2 %
Face Value 5.00
PEG Ratio9.90

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for

Competitors of

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,354 Cr. 308 390/12863.6 20.50.22 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 62.6 Cr. 84.4 94.9/26.624.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 35.9 Cr. 24.5 24.5/8.7446.6 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 86.7 Cr. 115 155/87.013.0 55.40.00 %14.4 %15.5 % 10.0
Glenmark Life Sciences Ltd 12,416 Cr. 1,013 1,335/64529.3 2072.22 %28.1 %21.1 % 2.00
Industry Average19,016.52 Cr1,181.3156.05186.300.32%16.20%16.32%6.27

All Competitor Stocks of

Quarterly Result

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales2,1342,1372,1082,1312,3472,2912,4912,4912,5912,6602,7322,7452,859
Expenses1,4571,4771,5701,5701,6351,6121,7671,7641,8001,8351,8631,8621,955
Operating Profit677660538561712679724727791825869883904
OPM %32%31%26%26%30%30%29%29%31%31%32%32%32%
Other Income405148-4293016-1093426553124
Interest68716257556910210710391808075
Depreciation165168167162155163193196191201213203197
Profit before tax484472357-87532463419433531559631631656
Tax %32%33%30%36%33%33%30%34%29%31%30%29%30%
Net Profit330316249-118354312292287378386443449457
EPS in Rs9.759.347.36-3.4910.469.228.638.4811.1711.4113.0913.2713.50

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales3,2034,1724,6366,6875,8165,9507,6737,9398,0058,5089,62010,72810,996
Expenses2,5063,2163,6163,9544,4384,6015,6905,7695,5246,0776,7787,3607,515
Operating Profit6979551,0202,7331,3771,3491,9832,1702,4802,4312,8423,3683,481
OPM %22%23%22%41%24%23%26%27%31%29%30%31%32%
Other Income13428632223299-30012157-28845146136
Interest3459175184206308504451353255333354326
Depreciation8387191238307409618654658662707808814
Profit before tax5828449402,3431,0889315621,1871,5261,2261,8472,3522,477
Tax %25%21%20%26%14%27%22%14%18%37%33%30%
Net Profit4356647511,7339346784361,0251,2527771,2451,6561,735
EPS in Rs12.7919.6222.1951.2227.5920.0412.8930.2836.9922.9736.7948.9451.27
Dividend Payout %45%25%25%34%25%35%66%53%47%105%60%57%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)52.64%13.10%130.76%-46.11%-27.41%-35.69%135.09%22.15%-37.94%60.23%33.01%
Change in YoY Net Profit Growth (%)0.00%-39.54%117.66%-176.86%18.70%-8.28%170.78%-112.95%-60.09%98.17%-27.22%

has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:10%
5 Years:7%
3 Years:10%
TTM:10%
Compounded Profit Growth
10 Years:9%
5 Years:22%
3 Years:8%
TTM:30%
Stock Price CAGR
10 Years:20%
5 Years:30%
3 Years:30%
1 Year:55%
Return on Equity
10 Years:23%
5 Years:21%
3 Years:21%
Last Year:24%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 6:41 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital42858585858585858585169169169
Reserves1,3801,8182,4063,4094,2664,5384,6404,7395,7535,8686,0296,6877,335
Borrowings6931,1322,7402,3522,5106,4626,0385,7844,8744,0705,3694,0223,128
Other Liabilities1,6381,9882,5893,0402,7403,1593,3513,4023,3632,8843,0433,6274,456
Total Liabilities3,7535,0227,8208,8869,60114,24314,11314,01014,07512,90614,61014,50515,088
Fixed Assets8208752,8332,8593,6887,8557,7487,5337,0656,4238,1218,1387,890
CWIP2855346781,042519647617712889630765361412
Investments601862987808044923532181226199173127
Other Assets2,5873,4274,0114,2064,5895,2495,3955,7635,9405,6285,5245,8346,659
Total Assets3,7535,0227,8208,8869,60114,24314,11314,01014,07512,90614,61014,50515,088

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +1535998102,7421,0098941,7981,3932,0051,8032,3683,266
Cash from Investing Activity +-247-418-2,113-869-798-4,677-246229-444-196-2,335-160
Cash from Financing Activity +20861,212-1,435-1933,417-1,314-1,549-1,651-1,78177-2,780
Net Cash Flow-73268-9043718-36623873-89-174110327

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow4.00954.00-1.000.00-1.00-5.00-5.00-3.00-2.00-2.00-3.00-1.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days7896125796077687669707463
Inventory Days364297275314318429318362456368298310
Days Payable421421472523356447345345351250224284
Cash Conversion Cycle22-28-71-1302159429317418814789
Working Capital Days334254-12820-17-282897453
ROCE %33%35%27%48%19%13%13%15%17%19%20%23%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%
FIIs11.53%11.63%10.88%10.80%11.37%12.09%12.04%12.85%13.15%14.08%14.14%14.22%
DIIs8.72%8.94%9.74%10.01%9.40%8.77%8.89%8.22%7.91%7.11%7.15%7.17%
Government0.00%0.00%0.00%0.00%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%
Public8.50%8.18%8.14%7.95%7.87%7.78%7.71%7.59%7.59%7.46%7.34%7.25%
No. of Shareholders64,30967,20563,22962,93367,86665,23763,83161,57269,61269,11771,15474,765

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Kotak Emerging Equity Fund - Regular Plan2,309,2531.5584.5353,6262024-12-18553.02%
UTI Flexi Cap Fund1,233,5121.24312.21353,6262024-12-18248.82%
SBI Large & Midcap Fund740,0020.94187.3353,6262024-12-18109.26%
Nippon India Pharma Fund603,3642.22152.72353,6262024-12-1870.62%
Kotak Small Cap Fund - Regular Plan463,7480.81117.38353,6262024-12-1831.14%
Axis Growth Opportunities Fund400,3400.93101.33353,6262024-12-1813.21%
Kotak Equity Arbitrage Fund - Regular Plan390,5000.2798.84353,6262024-12-1810.43%
Nippon India Value Fund353,6261.2889.51353,6262024-12-180%
Franklin India Bluechip Fund - Dividend350,0001.1988.59353,6262024-12-18-1.03%
Franklin India Bluechip Fund - Growth350,0001.1988.59353,6262024-12-18-1.03%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue5.005.005.005.005.00
Basic EPS (Rs.)48.9436.7945.9373.9860.55
Diluted EPS (Rs.)48.9436.7945.9373.9860.55
Cash EPS (Rs.)72.8257.6785.05112.8499.21
Book Value[Excl.RevalReserv]/Share (Rs.)202.57183.13351.75344.90284.99
Book Value[Incl.RevalReserv]/Share (Rs.)202.57183.13351.75344.90284.99
Revenue From Operations / Share (Rs.)316.96284.23502.72472.97469.12
PBDIT / Share (Rs.)101.2185.30155.27149.90135.41
PBIT / Share (Rs.)77.3364.43116.15111.0496.74
PBT / Share (Rs.)69.4954.5872.4490.1870.11
Net Profit / Share (Rs.)48.9436.7945.9273.9760.55
NP After MI And SOA / Share (Rs.)48.9436.7945.9273.9760.55
PBDIT Margin (%)31.9330.0130.8831.6928.86
PBIT Margin (%)24.3922.6623.1023.4720.62
PBT Margin (%)21.9219.2014.4019.0614.94
Net Profit Margin (%)15.4412.949.1315.6312.90
NP After MI And SOA Margin (%)15.4412.949.1315.6312.90
Return on Networth / Equity (%)24.1520.0913.0521.4421.24
Return on Capital Employeed (%)27.1622.7922.6320.4619.13
Return On Assets (%)10.998.295.938.897.31
Long Term Debt / Equity (X)0.230.400.350.500.67
Total Debt / Equity (X)0.570.850.670.820.90
Asset Turnover Ratio (%)0.710.680.530.500.47
Current Ratio (X)1.030.971.201.130.91
Quick Ratio (X)0.610.560.640.580.51
Inventory Turnover Ratio (X)0.730.630.680.690.78
Dividend Payout Ratio (NP) (%)61.2969.3087.0927.0359.45
Dividend Payout Ratio (CP) (%)41.1944.2147.0217.7236.28
Earning Retention Ratio (%)38.7130.7012.9172.9740.55
Cash Earning Retention Ratio (%)58.8155.7952.9882.2863.72
Interest Coverage Ratio (X)9.698.6610.307.195.08
Interest Coverage Ratio (Post Tax) (X)5.434.735.954.553.27
Enterprise Value (Cr.)91136.9056758.9950939.2747229.2337065.09
EV / Net Operating Revenue (X)8.505.905.995.904.67
EV / EBITDA (X)26.6019.6619.3818.6216.17
MarketCap / Net Operating Revenue (X)8.215.415.565.374.20
Retention Ratios (%)38.7030.6912.9072.9640.54
Price / BV (X)12.848.397.957.376.92
Price / Net Operating Revenue (X)8.215.415.565.374.20
EarningsYield0.010.020.010.020.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of as of December 22, 2024 is: 3,617.83

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 22, 2024, is Undervalued by 5.26% compared to the current share price 3,437.00

Intrinsic Value of as of December 22, 2024 is: 3,861.93

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 22, 2024, is Undervalued by 12.36% compared to the current share price 3,437.00

Last 5 Year EPS CAGR: 6.75%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 23.50%, which is a positive sign.
  2. The company has higher reserves (4,528.31 cr) compared to borrowings (3,782.62 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (6.62 cr) and profit (297.69 cr) over the years.
  1. The stock has a high average Working Capital Days of 37.92, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 50.50, which may not be favorable.
  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in :
    1. Net Profit Margin: 15.44%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 27.16% (Industry Average ROCE: 16.2%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 24.15% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 5.43
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.61
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 66.8 (Industry average Stock P/E: 56.05)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.57
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Torrent Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/07/1972 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1972PLC002126 and registration number is 002126. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 6742.32 Cr. and Equity Capital is Rs. 84.62 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsTorrent House, Off Ashram Road, Ahmedabad Gujarat 380009investorservices@torrentpharma.com
http://www.torrentpharma.com
Management
NamePosition Held
Mr. Sudhir MehtaChairman Emeritus
Mr. Samir MehtaExecutive Chairman
Mr. Aman Samir MehtaWhole Time Director
Mr. Jinesh ShahDirector - Operations
Mr. Jinal MehtaNon Executive Director
Mr. Manish Mahendra ChoksiIndependent Director
Dr. Maurice ChagnaudIndependent Director
Mr. Nikhil KhattauIndependent Director
Ms. Ameera ShahIndependent Director
Ms. Nayantara BaliIndependent Director

FAQ

What is the latest intrinsic value of ?

The latest intrinsic value of as on 22 December 2024 is ₹3617.83, which is 5.26% higher than the current market price of ₹3,437.00. The stock has a market capitalization of 1,16,318 Cr. and recorded a high/low of 3,591/2,223 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹7,335 Cr and total liabilities of ₹15,088 Cr.

What is the Market Cap of ?

The Market Cap of is 1,16,318 Cr..

What is the current Stock Price of as on 22 December 2024?

The current stock price of as on 22 December 2024 is 3,437.

What is the High / Low of stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of stocks is 3,591/2,223.

What is the Stock P/E of ?

The Stock P/E of is 66.8.

What is the Book Value of ?

The Book Value of is 222.

What is the Dividend Yield of ?

The Dividend Yield of is 0.81 %.

What is the ROCE of ?

The ROCE of is 23.2 %.

What is the ROE of ?

The ROE of is 24.2 %.

What is the Face Value of ?

The Face Value of is 5.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in . Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE